Actively Recruiting
Investigation of Safety and Effectiveness of Ondexxya 200 mg Intravenous Injection in Patients with Life-Threatening Bleeding Related to Factor Xa Inhibitors
Led by AstraZeneca · Updated on 2026-10-13
300
Participants Needed
54
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.
CONDITIONS
Brief Title
Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here